Disc Medicine, Inc. (NASDAQ:IRON) CFO Jean M. Franchi Sells 2,031 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CFO Jean M. Franchi sold 2,031 shares of the stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $59.00, for a total transaction of $119,829.00. Following the completion of the sale, the chief financial officer directly owned 63,499 shares in the company, valued at approximately $3,746,441. This trade represents a 3.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Disc Medicine Stock Down 0.0%

NASDAQ:IRON traded down $0.02 during trading hours on Friday, reaching $57.77. 672,319 shares of the stock were exchanged, compared to its average volume of 341,618. The stock has a market cap of $2.00 billion, a PE ratio of -14.74 and a beta of 0.76. The company has a debt-to-equity ratio of 0.04, a current ratio of 37.65 and a quick ratio of 37.65. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $68.73. The firm has a 50 day moving average of $51.05 and a 200 day moving average of $51.61.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03). On average, equities analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. BMO Capital Markets raised their price target on shares of Disc Medicine from $112.00 to $120.00 and gave the stock an "outperform" rating in a report on Monday, May 12th. Raymond James Financial assumed coverage on shares of Disc Medicine in a research note on Wednesday, June 11th. They issued a "strong-buy" rating and a $89.00 target price on the stock. Wedbush reiterated an "outperform" rating and set a $90.00 price target on shares of Disc Medicine in a research report on Monday, June 16th. HC Wainwright reissued a "buy" rating and set a $118.00 price objective on shares of Disc Medicine in a report on Thursday, July 3rd. Finally, Morgan Stanley started coverage on Disc Medicine in a report on Thursday, July 3rd. They set an "overweight" rating and a $85.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $96.70.

Institutional Investors Weigh In On Disc Medicine

Large investors have recently added to or reduced their stakes in the business. Amalgamated Bank raised its stake in Disc Medicine by 38.6% in the 1st quarter. Amalgamated Bank now owns 787 shares of the company's stock valued at $39,000 after acquiring an additional 219 shares during the period. Renaissance Technologies LLC bought a new stake in Disc Medicine in the 4th quarter valued at $5,479,000. Rhumbline Advisers increased its position in Disc Medicine by 10.7% during the 1st quarter. Rhumbline Advisers now owns 32,144 shares of the company's stock worth $1,596,000 after buying an additional 3,108 shares during the period. GAMMA Investing LLC increased its position in Disc Medicine by 5,092.5% during the 1st quarter. GAMMA Investing LLC now owns 12,410 shares of the company's stock worth $616,000 after buying an additional 12,171 shares during the period. Finally, Ameriprise Financial Inc. bought a new position in Disc Medicine during the 4th quarter worth $335,000. Institutional investors own 83.70% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.